Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.,Journal of the Pediatric Infectious Diseases Society

当前位置： X-MOL 学术 › J. Pediat. Inf. Dis. Soc. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.
Journal of the Pediatric Infectious Diseases Society ( IF 2.5 ) Pub Date : 2020-05-25 , DOI: 10.1093/jpids/piaa039
Paul Krogstad ₁ , Pearl Samson ₂ , Edward P Acosta ₃ , Jack Moye ₄ , Ellen Townley ₅ , Sarah Bradford ₆ , Emily Brown ₆ , Kayla Denson ₇ , Bobbie Graham ₇ , Laura Hovind ₇ , Thucuma Sise ₅ , Hedy Teppler ₈ , Sisinyana Ruth Mathiba ₉ , Lee Fairlie ₁₀ , Jana L Winckler ₁₁ , Gretchen Slade ₁₂ , Tammy Meyers ₁₃ ,

Affiliation

Departments of Pediatrics and Molecular and Medical Pharmacology, David Geffen School of Medicine at Los Angeles, Los Angeles, California, USA.
Statistical and Data Management Center, Frontier Science Foundation/Harvard T.H. Chan School of Public Health Boston, Massachusetts, USA.
Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Maternal and Pediatric Infectious Disease Branch, Division of Extramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA.
Columbus Technologies and Services, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
FHI360, Durham, North Carolina, USA.
Frontier Science Foundation, Inc, Amherst, New York, USA.
Global Clinical Development - Infectious Diseases, Merck & Co, Inc, Kenilworth, New Jersey, USA.
Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Desmond Tutu TB Centre, Department of Paediatrics, Stellenbosch University, Cape Town South Africa.
Department of Paediatrics and Child Health, Family Clinical Research Unit, Stellenbosch University, Cape Town, South Africa.
Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB. CLINICAL TRIALS REGISTRATION NCT01751568.

中文翻译：

含有拉替拉韦的治疗方案在感染人类免疫缺陷病毒并接受利福平治疗结核病的 4 周至 2 岁儿童中的药代动力学和安全性。

药理学相互作用限制了感染人类免疫缺陷病毒 (HIV) 和结核病 (TB) 的儿童的治疗选择。我们发现，12 mg/kg 每日两次的拉替拉韦咀嚼片（压碎后给药）在 4 周至 2 岁以下同时接受利福平治疗结核病的 HIV 感染儿童中安全地达到了药代动力学目标。临床试验注册 NCT01751568。

更新日期：2020-05-25

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11